Gross Margin % is calculated as gross profit divided by its revenue. Biocept's Gross Profit for the
three
months ended in Jun. 2023 was $-1.96 Mil. Biocept's Revenue for the
three
months ended in Jun. 2023 was $0.59 Mil. Therefore, Biocept's Gross Margin % for the quarter that ended in Jun. 2023 was -332.94%.
The historical rank and industry rank for Biocept's Gross Margin % or its related term are showing as below:
BIOCQ'
s Gross Margin % Range Over the Past 10 Years
Min: -1638.81 Med: -106.63 Max: 38.34
Current: -1055.02
During the past 12 years, the highestGross Margin % of Biocept was 38.34%. The lowest was -1638.81%. And the median was -106.63%.
BIOCQ's Gross Margin % is ranked worse than 100% of 216
companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595
vs BIOCQ: -1055.02
Biocept had a gross margin of -332.94% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Biocept was 0.00% per year.
Biocept Gross Margin % Historical Data
The historical data trend for Biocept's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biocept's Gross Margin %
For the Diagnostics & Research subindustry, Biocept's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocept's Gross Margin % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Biocept's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biocept (OTCPK:BIOCQ) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biocept had a gross margin of -332.94% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biocept Gross Margin % Related Terms
Thank you for viewing the detailed overview of Biocept's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOCQ has been successfully added to your 